A group of independent scientists conducted a study on Molnupiravir, the world’s first COVID-19 drug developed by Merck. Experts, as a result of their examinations, explained that the benefit of the drug is more than the harm, and therefore it should be approved for use.
In a content we shared with you a while ago, we have the world’s first developed by Merck. of COVID-19 medicine has been submitted for immediate use approval. we talked about. Now, there has been an important development on this issue. A special committee of completely independent experts recommended that the benefit of the drug outweighs the harm, so approval should be given. Eyes, US Federal Food and Drug Administration (FDA) in the final decision to be made by…
Scientists who have completed their work on the drug called molnupiravir, use this drug especially for the elderly with mild to moderate COVID-19 and people with diseases such as diabetes. they recommend. The drug, which is understood to be unsuitable for pregnant women, is also available for vaccinated people not covered by clinical trials. not recommended.
It is also thought to be effective for the variant named Omicron.
Independent scientists voted 13 by 10 they came to a decision. So, most experts argued that this drug should be approved and made available.
RELATED NEWS
Both Hopeful and Suspicious Statement About the Omicron Variant
Merck officials, who made statements about molnupiravir, based on previous data; of the drug omicron They think it will also be effective for the variant named. However, there is not enough data on this subject. As a result of clinical studies, the rate of hospitalization and death rate 30 percent (previously declared to be 50 percent), it seems that the drug that lowers it will allow us to enter a new crossroads in the COVID-19 epidemic.
Source :
https://www.ntv.com.tr/saglik/abddecovid-19ilacimolnupiravireilk-onay,dDRkODU430WDKz4rWn5GPQ